# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
New science for cancer therapy drives powerful value propositionExceptional measures of efficacy by lead drug THIO in Phase 2 c...
Original seed investor has remained top MAIA stockholderMAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company...